This week Evusheld has become the first pre-exposure prophylaxis for COVID-19; Data shows that the Pfizer-BioNTech booster dose ups protection against Omicron; Monoclonal antibody therapy is authorized for children; Heterologous boosting may be more beneficial than homogeneous; And important information regarding Veklury.